Human menopausal gonadotrophin in a pre-filled injection pen is non-inferior to the US-approved powder formulation.
Reprod Biomed OnlineJun 10, 2026 (epub)
Clinical ResearchObstetrics & Gynecology
Craig Witz, Eric D Foster, Sarah A Grover et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the non-inferiority of human menopausal gonadotrophin (HP-HMG) in a pre-filled injection pen compared to the HP-HMG powder formulation in 401 women aged 18-42 undergoing ovarian stimulation. The study found that the mean number of fertilized oocytes was 8.2 with the pen versus 6.6 with the powder, demonstrating non-inferiority.
Key findings
- Mean number of fertilized 2PN oocytes was 8.2 ± 5.5 for the pen and 6.6 ± 4.3 for the powder.
- The number of oocytes retrieved was 14.3 ± 8.1 with the pen compared to 11.4 ± 6.3 with the powder.
- Ongoing pregnancy rate was 45.0% for the pen group and 42.7% for the powder group.
- Live birth rate after fresh transfer was 44.1% for the pen and 42.2% for the powder.
Why it matters
The findings support the use of HP-HMG in a pre-filled injection pen as a viable alternative to the traditional powder formulation, potentially improving patient convenience and adherence during ovarian stimulation.